Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity

Biochemical and Biophysical Research Communications

Volumn 396, Issue 2, 2010, Pages 566-570

  Matsui, Takanori ^a   Takeuchi, Masayoshi ^b   Yamagishi, Sho ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGE; Aldosterone; Inflammation; Mineralocorticoid receptor; Nifedipine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDOSTERONE; COLLAGEN TYPE 3; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NIFEDIPINE; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; FIBROBLAST; FIBROSIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION;

ALDOSTERONE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIUM CHANNEL BLOCKERS; CELL LINE; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; NIFEDIPINE; RECEPTORS, MINERALOCORTICOID;

EID: 77952745260     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.04.149     Document Type: Article

References (30)

1. Rahbar S. The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems. Ann. NY. Acad. Sci. USA 1043 (2005) 9-19
2. Vlassara H., and Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 45 (1996) S65-S66
3. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 11 (2005) 2279-2299
4. Yamagishi S., Fukami K., Ueda S., and Okuda S. Molecular mechanisms of diabetic nephropathy, its therapeutic, intervention. Curr. Drug Targets 8 (2007) 952-959
5. Yamagishi S., Matsui T., and Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr. Drug Targets 8 (2007) 1138-1143
6. Schmidt A.M., and Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr. Atheroscler. Rep. 2 (2000) 430-436
7. Liu Y., Liang C., Liu X., Liao B., Pan X., Ren Y., Fan M., Li M., He Z., Wu J., and Wu Z. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 208 (2010) 34-43
8. Chen S.C., Guh J.Y., Hwang C.C., Chiou S.J., Lin T.D., Ko Y.M., Huang J.S., Yang Y.L., and Chuang L.Y. Advanced glycation end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal, fibroblasts. J. Cell Biochem. 109 (2010) 38-48
9. Li J.H., Wang W., Huang X.R., Oldfield M., Schmidt A.M., Cooper M.E., and Lan H.Y. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2MAP kinase signaling pathway. Am. J. Pathol. 164 (2004) 1389-1397
10. Daound S., Schinzel R., Neumann A., Loske C., Fraccarollo D., Diez C., and Simm A. Advanced glycation end products: activators of cardiac remodeling in primary fibroblasts from adult rat hearts. Mol. Med. 7 (2001) 543-551
11. NIshioka T., Suzuki M., Onishi K., Takakura N., Inada H., Yoshida T., Horie M., and Imanaka-Yoshida K. Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. J. Cardiovasc. Pharmacol. 49 (2007) 261-268
12. Cortinovis M., Perico N., Cattaneo D., and Remuzzi G. Aldosterone and progression of kidney disease. Ther. Adv. Cardiovasc. Dis. 3 (2008) 133-143
13. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., Han K.H., Kim H.K., Kang Y.S., Han J.Y., Kim Y.S., and Cha D.R. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol. 17 (2006) 1362-1372
14. Berry C., Tardif J.C., and Bourassa M.G. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J. Am. Coll. Cardiol. 49 (2007) 631-642
15. Whaley-Connell A., and Sowers J.R. Hypertension management in type 2 diabetes mellitus: recommendations of the joint national committee VII. Endocrinol. Metab. Clin. North Am. 34 (2005) 63-75
16. Mancia G. Optimal control of blood pressure in patients with diabetes reduces the incidence of macro, microvascular, events. J. Hypertens. Suppl. 1 (2007) S7-S12
17. Yamagishi S., and Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp. Clin. Res. 30 (2004) 169-175
18. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., and Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferators-activated receptor-gamma activation. Biochem. Biophys. Res. Commun. 385 (2009) 269-272
19. Yamagishi S., Nakamura K., and Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr. Med. Chem. 15 (2008) 172-177
20. Dietz J.D., Du S., Bolten C.W., Payne M.A., Xia C., Blinn J.R., Funder J.W., and Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 51 (2008) 742-748
21. Honada E., and Munakata H. Purification, characterization of decorin from the culture media of MRC-5 cells. Int. J. Biochem. Cell Biol. 36 (2004) 1635-1644
22. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., and Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem. 281 (2006) 20213-20220
23. Ohtani T., Ohta M., Yamamoto K., Mano T., Sakata Y., Nishio M., Takeda Y., Yoshida J., Miwa T., Okamoto M., Masuyama T., Nonaka Y., and Hori M. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 (2007) R946-R954
24. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., and Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 69 2006 (2006) 73-80
25. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1950-1959
26. Bujak M., and Frangogiannis N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 74 (2007) 184-195
27. Leask A., and Abraham D.J. TGF-beta signaling and the fibrotic response. FASEB J. 18 (2004) 816-827
28. Sharma K., and Ziyadeh F.N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 44 (1995) 1139-1146
29. Takeuchi M., Makita Z., Yanagisawa K., Kameda K., and Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5 (1999) 393-405
30. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., and Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 49 (2006) 3094-3099